Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine B Bevans

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Journal of Patient-Reported Outcomes|November 7, 2021
Development and equivalence of new faces for inclusion in the Childhood Asthma Control Test (C-ACT) response scaleKate Sully, Nicola Bonner, Helena Bradley, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
European Urology Oncology|December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate CancerEric J Small, Kim N Chi, Simon Chowdhury, et al.
Journal of Pediatric Psychology|October 20, 2017
Development and Content Validation of the Transition Readiness Inventory Item Pool for Adolescent and Young Adult Survivors of Childhood CancerLisa A Schwartz, Jessica L Hamilton, Lauren D Brumley, et al.
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyKim N Chi, Simon Chowdhury, Anders Bjartell, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of Patient-Reported Outcomes|November 7, 2021
Development and equivalence of new faces for inclusion in the Childhood Asthma Control Test (C-ACT) response scaleKate Sully, Nicola Bonner, Helena Bradley, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
European Urology Oncology|December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate CancerEric J Small, Kim N Chi, Simon Chowdhury, et al.
Journal of Pediatric Psychology|October 20, 2017
Development and Content Validation of the Transition Readiness Inventory Item Pool for Adolescent and Young Adult Survivors of Childhood CancerLisa A Schwartz, Jessica L Hamilton, Lauren D Brumley, et al.
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyKim N Chi, Simon Chowdhury, Anders Bjartell, et al.
Pageof 6